Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Oct;70(4):724–728. doi: 10.1038/bjc.1994.383

Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics.

M T Seymour 1, N Patel 1, A Johnston 1, S P Joel 1, M L Slevin 1
PMCID: PMC2033410  PMID: 7917928

Abstract

The disposition of 5-fluorouracil (FUra) was studied in 19 colorectal cancer patients during treatment with FUra and high-dose leucovorin (LV) with or without interferon alpha 2a (IFN-alpha). All received LV 200 mg m-2 over 2 h, then FUra 400 mg m-2 over 5 min then FUra 400 mg m-2 over 22 h, repeated on day 2, on a 14 day cycle. Nine patients also received IFN-alpha 6 MU every 48 h, starting at least 2 weeks before the study. Series of 14 blood samples were assayed for FUra by reversed-phase high-performance liquid chromatography (HPLC). Minimum Akaike information criterion estimation was used to determine the simplest effective pharmacokinetic model. This consisted of a single compartment with first-order (linear) and Michaelis-Menten (non-linear) components to drug elimination. This model gave r2 > 0.98 in 19/20 data sets. With the Michaelis constant (KM) set at 15 microM, values were derived for the volume of distribution (Vd), the maximum rate of non-linear elimination (Vmax) and the first-order elimination rate constant (K1.e). Mean (+/- s.d.) values in control (no IFN-alpha) patients were: Vd 10.4 (+/- 1.9) l m-2, Vmax 182 (+/- 59) mumol l-1 h-1 and k1.e 4.35 (+/- 0.58) h-1. No significant differences were detected in patients receiving IFN-alpha, in whom the equivalent mean values were Vd 10.0 (+/- 0.9) l m-2, Vmax 141 (+/- 27) mumol l-1 h-1 and k1.e 3.96 (+/- 0.5) h-1. Mean trapezoidal AUC0-22 h was similar in the two groups (control patients 116 microM h, IFN-alpha patients 125 microM h). No significant correlations with renal or hepatic function were detected. These results, while not inconsistent with previous reports of a reduced rate of FUra elimination at higher IFN-alpha doses, suggest that any clinical effect of this moderate dose of IFN-alpha on FUra toxicity or activity is due to modulation at target cells, not to pharmacokinetic interaction.

Full text

PDF
724

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Christophidis N., Mihaly G., Vajda F., Louis W. Comparison of liquid- and gas-liquid chromatographic assays of 5-fluorouracil in plasma. Clin Chem. 1979 Jan;25(1):83–86. [PubMed] [Google Scholar]
  2. Chu E., Zinn S., Boarman D., Allegra C. J. Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res. 1990 Sep 15;50(18):5834–5840. [PubMed] [Google Scholar]
  3. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  4. Collins J. M., Dedrick R. L., King F. G., Speyer J. L., Myers C. E. Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther. 1980 Aug;28(2):235–246. doi: 10.1038/clpt.1980.156. [DOI] [PubMed] [Google Scholar]
  5. Coustère C., Mentré F., Sommadossi J. P., Diasio R. B., Steimer J. L. A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. Cancer Chemother Pharmacol. 1991;28(2):123–129. doi: 10.1007/BF00689701. [DOI] [PubMed] [Google Scholar]
  6. Danhauser L. L., Freimann J. H., Jr, Gilchrist T. L., Gutterman J. U., Hunter C. Y., Yeomans A. C., Markowitz A. B. Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. J Clin Oncol. 1993 Apr;11(4):751–761. doi: 10.1200/JCO.1993.11.4.751. [DOI] [PubMed] [Google Scholar]
  7. De Gramont A., Krulik M., Cady J., Lagadec B., Maisani J. E., Loiseau J. P., Grange J. D., Gonzalez-Canali G., Demuynck B., Louvet C. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol. 1988 Sep;24(9):1499–1503. doi: 10.1016/0277-5379(88)90341-0. [DOI] [PubMed] [Google Scholar]
  8. Grem J. L., McAtee N., Murphy R. F., Balis F. M., Steinberg S. M., Hamilton J. M., Sorensen J. M., Sartor O., Kramer B. S., Goldstein L. J. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. J Clin Oncol. 1991 Oct;9(10):1811–1820. doi: 10.1200/JCO.1991.9.10.1811. [DOI] [PubMed] [Google Scholar]
  9. Houghton J. A., Adkins D. A., Rahman A., Houghton P. J. Interaction between 5-fluorouracil, [6RS]leucovorin, and recombinant human interferon-alpha 2a in cultured colon adenocarcinoma cells. Cancer Commun. 1991 Jul;3(7):225–231. doi: 10.3727/095535491820873236. [DOI] [PubMed] [Google Scholar]
  10. Houghton J. A., Morton C. L., Adkins D. A., Rahman A. Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-alpha 2a in colon carcinoma cells. Cancer Res. 1993 Sep 15;53(18):4243–4250. [PubMed] [Google Scholar]
  11. Kreuser E. D., Hilgenfeld R. U., Matthias M., Hoksch B., Boewer C., Oldenkott B., Knauf W. U., Boese-Landgraf J., Schalhorn A., Zeitz M. A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. Semin Oncol. 1992 Apr;19(2 Suppl 3):197–203. [PubMed] [Google Scholar]
  12. Naguib F. N., el Kouni M. H., Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res. 1985 Nov;45(11 Pt 1):5405–5412. [PubMed] [Google Scholar]
  13. Pittman K., Perren T., Ward U., Primrose J., Slevin M., Patel N., Selby P. Pharmacokinetics of 5-fluorouracil in colorectal cancer patients receiving interferon. Ann Oncol. 1993 Jun;4(6):515–516. doi: 10.1093/oxfordjournals.annonc.a058564. [DOI] [PubMed] [Google Scholar]
  14. Schwartz E. L., Hoffman M., O'Connor C. J., Wadler S. Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells. Biochem Biophys Res Commun. 1992 Feb 14;182(3):1232–1239. doi: 10.1016/0006-291x(92)91863-l. [DOI] [PubMed] [Google Scholar]
  15. Schüller J., Czejka M. J., Schernthaner G., Fogl U., Jäger W., Micksche M. Influence of interferon alfa-2b with or without folinic acid on pharmacokinetics of fluorouracil. Semin Oncol. 1992 Apr;19(2 Suppl 3):93–97. [PubMed] [Google Scholar]
  16. Sparano J. A., Wadler S., Diasio R. B., Zhang R., Lu Z., Schwartz E. L., Einzig A., Wiernik P. H. Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. J Clin Oncol. 1993 Aug;11(8):1609–1617. doi: 10.1200/JCO.1993.11.8.1609. [DOI] [PubMed] [Google Scholar]
  17. Wadler S., Schwartz E. L. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res. 1990 Jun 15;50(12):3473–3486. [PubMed] [Google Scholar]
  18. Yamaoka K., Nakagawa T., Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978 Apr;6(2):165–175. doi: 10.1007/BF01117450. [DOI] [PubMed] [Google Scholar]
  19. Yee L. K., Allegra C. J., Steinberg S. M., Grem J. L. Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon alpha-2a. J Natl Cancer Inst. 1992 Dec 2;84(23):1820–1825. doi: 10.1093/jnci/84.23.1820. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES